KR20170119422A - Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum - Google Patents
Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum Download PDFInfo
- Publication number
- KR20170119422A KR20170119422A KR1020160047400A KR20160047400A KR20170119422A KR 20170119422 A KR20170119422 A KR 20170119422A KR 1020160047400 A KR1020160047400 A KR 1020160047400A KR 20160047400 A KR20160047400 A KR 20160047400A KR 20170119422 A KR20170119422 A KR 20170119422A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- piper
- skin
- composition
- cambodianum
- Prior art date
Links
- 241000009298 Trigla lyra Species 0.000 title claims abstract description 104
- 239000000284 extract Substances 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 239000002537 cosmetic Substances 0.000 title claims description 35
- 230000000694 effects Effects 0.000 claims abstract description 53
- 230000029663 wound healing Effects 0.000 claims abstract description 21
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 15
- 102000008186 Collagen Human genes 0.000 claims abstract description 15
- 229920001436 collagen Polymers 0.000 claims abstract description 15
- 108010014258 Elastin Proteins 0.000 claims abstract description 12
- 102000016942 Elastin Human genes 0.000 claims abstract description 12
- 229920002549 elastin Polymers 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 230000006872 improvement Effects 0.000 claims abstract description 11
- 206010052428 Wound Diseases 0.000 claims description 22
- 208000027418 Wounds and injury Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 230000032683 aging Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 abstract description 10
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- -1 etc. Substances 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 230000002500 effect on skin Effects 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 241000819999 Nymphes Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000004952 protein activity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960005082 etohexadiol Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 파이퍼 캄보디아눔 추출물을 포함하는 피부개선용 조성물에 관한 것으로, 본 발명의 파이퍼 캄보디아눔 추출물은 천연 추출물로 인체에 무해할 뿐 아니라, 콜라겐(collagen), 엘라스틴(Elastin) 및 HAS-2 유전자의 발현을 증가시키고 MMP-1 유전자의 발현 및 ROS 활성을 저해함으로써 우수한 항산화, 항노화 효과 및 상처치료 효과를 나타내므로 피부개선용 조성물, 상처치료용 조성물 및 항산화용 조성물 등으로 유용하게 활용할 수 있다.The present invention relates to a composition for improving skin comprising Piper cambodiaeum. The extract of Piper cambodiae of the present invention is a natural extract, harmless to the human body, and also contains collagen, elastin and HAS-2 gene And exhibits excellent antioxidative, anti-aging and wound healing effects by inhibiting the expression of the MMP-1 gene and ROS activity, and thus can be effectively utilized as a composition for skin improvement, a composition for wound healing, and a composition for antioxidation .
Description
본 발명은 파이퍼 캄보디아눔 (Piper cambodianum) 추출물을 포함하는 피부개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin comprising Piper cambodianum extract.
피부는 인체의 대부분을 차지하며 체온조절, 분비, 배설, 흡수 등의 다양한 작용을 하고, 특히 인체의 최외부에 존재함으로써 외부로부터 물리적, 화학적, 생물학적으로 인체를 보호하는 기능을 가진다. 피부는 표피, 진피, 피하지방으로 이루어져 있으며, 표피는 인체의 외부와 내부로부터 방어작용을 하고, 진피는 피부의 탄력 및 지지 역할, 피하지방은 체온을 유지하는 기능을 가진다.The skin occupies most of the human body and has various functions such as body temperature control, secretion, excretion, absorption, and especially functions to protect the human body physically, chemically and biologically from outside by being present at the outermost part of the human body. The skin is composed of epidermis, dermis and subcutaneous fat. The epidermis protects from the outside and inside of the body. The dermis has the function of supporting elasticity and support of skin, and subcutaneous fat has the function of maintaining body temperature.
콜라겐 분해효소인 기질 금속 단백질 분해 효소(Matrix Metalloproteinase; MMP)라는 효소는 노화방지 및 상처개선에 관여한다. 즉, 생체 내에서 콜라겐과 같은 세포외기질의 합성과 분해는 적절하게 조절되나, 노화가 진행되거나 자외선 조사에 의해 콜라겐 합성이 감소하고, 콜라겐을 분해하는 효소인 기질 금속 단백질 분해 효소(MMP)의 발현이 촉진되어 피부의 탄력이 저하되고 주름이 형성된다. 또한 콜라겐을 분해하는 기질 금속 단백질 분해 효소의 발현이 감소되면 상처가 잘 아물지 않게 된다.An enzyme called matrix metalloproteinase (MMP), a collagenase, is involved in anti-aging and wound healing. That is, although synthesis and degradation of extracellular matrix such as collagen in vivo are appropriately controlled, collagen synthesis is reduced by aging or ultraviolet irradiation, and expression of matrix metalloproteinase (MMP), an enzyme that degrades collagen, The elasticity of the skin is lowered and wrinkles are formed. In addition, when the expression of collagen-degrading matrix metalloproteinase is reduced, the wound is not healed well.
한편, 활성 산소종은 여러 신호전달 과정을 변경하여 유전자 발현, 세포흡착, 물질대사, 세포주기, 세포사멸에 영향을 주는 것으로 알려져 있으며, 활성 산소종이 유도하는 신호전달에는 MAPK(mitogen-activated protein kinase), NF-κB (nuclear factor-κB), PI3K(phosphatidylinositol 3-kinase), p53, β-catenin/Wnt를 매개로 하는 신호전달이 알려져 있다. 최근, 활성 산소종에 의한 인체 내 손상을 보호하는 항산화를 통한 노화방지에 대한 연구가 다양하게 이루어지고 있다.On the other hand, reactive oxygen species are known to alter gene expression, cell adsorption, metabolism, cell cycle, and apoptosis by altering various signal transduction processes. Activated oxygen species are involved in signal transduction induced by reactive oxygen species such as mitogen-activated protein kinase ), NF-κB (nuclear factor-κB), phosphatidylinositol 3-kinase (PI3K), p53 and β-catenin / Wnt. Recently, there have been various studies on anti-aging through antioxidation that protects the human body from damage by active oxygen species.
잘 먹고 잘사는 웰빙(well-being) 트랜드에 부응하여, 상기와 같이 보호, 탄력 및 지지역할을 하는 피부에 이용하기 위한 화장품은 선택이 아닌 필수 요소로서 부가가치가 높은 산업으로 자리잡아 가고 있고, 소비자들은 현재 널리 사용되고 있는 화학 합성물질이 아닌 천연자원을 이용한, 고품질의 제품을 선호하는 현상이 두드러지고 있으며, 이러한 소비자의 요구에 부합하여 화장품 및 건강기능식품 시장에서도 기능성 화장품 및 기능성 식품과 같은 화장품과 의약품의 중간 단계의 약학적 치료 효능을 가진 천연 자원을 바탕으로 하는 기능성 화장품에 대한 개발이 각광받고 있다. 이에 천연물, 미생물, 단백질 배양액, 줄기세포 유래 배양액까지 화장품의 원료로 이용될 수 있는 다양한 소재 개발이 진행되고 있다.In response to the well-being trend of eating well and living well, cosmetics for use in skin that acts as protection, elasticity, and support as described above are becoming an indispensable element rather than an option, Are preferring high quality products using natural resources, which are not widely used chemically synthesized materials. In line with these consumer needs, cosmetics such as functional cosmetics and functional foods, The development of functional cosmetics based on natural resources with medicinal efficacy at the intermediate stage of pharmaceuticals is attracting attention. Accordingly, various materials that can be used as raw materials for cosmetics, such as natural products, microorganisms, protein cultures, and stem cell-derived cultures, are under development.
특히, 최근에는 화장품 성분의 유전자 변형이나 환경 호르몬으로 인한 문제점이 대두되면서 장기적으로 인체에 유해하지 않고 안전하게 사용할 수 있는 천연물질 추출물을 주성분으로 하는 기능성 화장품에 기대가 높아지고 있다.In particular, recently, problems arise due to genetic modification of cosmetic ingredients and environmental hormones, so that functional cosmetics based on extracts of natural substances that can be safely used without being harmful to the human body in the long term are increasingly expected.
한편, 파이퍼 캄보디아눔 (Piper cambodianum)은 베트남을 원산지로 하는 후추과의 식물로서 아직까지 학명이 알려지지 않았으며 그 효과 또한 거의 연구된 바 없다.On the other hand, Piper cambodianum is a plant belonging to the genus Piper , originating in Vietnam, and its scientific name has not yet been known.
본 발명자들은 천연물질을 이용한 기능성 화장품을 연구하던 중 파이퍼 캄보디아눔 추출물이 기질 금속 단백질 분해 효소(MMP)의 억제 및 활성산소종의 감소를 통한 우수한 상처치유 효과를 나타내며, 항산화 및 주름개선을 통한 항노화 효과를 나타내는 것을 확인하고 본 발명을 완성하였다.The inventors of the present invention found that Piper cambodia nymph extract exhibits excellent wound healing effects through inhibition of substrate metalloproteinase (MMP) and reduction of reactive oxygen species while studying functional cosmetics using natural substances, Aging effect and completed the present invention.
발명의 목적은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 피부개선용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for improving skin comprising Piper cambodianum extract.
본 발명의 또 다른 목적은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 상처치료용 조성물을 제공하는 것이다.It is another object of the present invention to provide a composition for treating wounds comprising Piper cambodianum extract.
본 발명의 또 다른 목적은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 항산화용 조성물을 제공하는 것이다.It is another object of the present invention to provide a composition for antioxidation comprising Piper cambodianum extract.
상기 목적을 달성하기 위하여, 본 발명은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 피부개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for skin improvement comprising Piper cambodianum extract.
또한, 본 발명은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 상처치료용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the treatment of wounds comprising Piper cambodianum extract.
또한, 본 발명은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 상처치료용 피부외용제 조성물을 제공한다.The present invention also provides a composition for external application for skin for wound healing, which comprises Piper cambodianum extract.
또한, 본 발명은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 항산화용 또는 상처개선용 건강기능식품 조성물을 제공한다. The present invention also provides an antioxidant or wound-healing health functional food composition containing Piper cambodianum extract.
본 발명의 파이퍼 캄보디아눔(Piper cambodianum)의 추출물은 천연 추출물로 인체에 무해할 뿐 아니라, 콜라겐(collagen), 엘라스틴(Elastin) 및 HAS-2 유전자의 발현을 증가시키고 MMP-1 유전자의 발현 및 ROS 활성을 저해함으로써 우수한 항산화, 항노화 효과 및 상처치료 효과를 나타내므로 피부개선용 조성물, 상처치료용 조성물 및 항산화용 조성물 등으로 유용하게 활용할 수 있다.The extract of Piper cambodianum of the present invention is a natural extract, which is not only harmless to human body but also increases the expression of collagen, elastin and HAS-2 gene, and the expression of MMP-1 gene and ROS Inhibiting activity of the present invention exhibits excellent antioxidation, anti-aging effect and wound healing effect, it can be effectively utilized as a composition for skin improvement, a composition for wound healing, and a composition for antioxidation.
도 1은 본 발명에서 사용된 파이퍼 캄보디아눔의 잎과 나무의 외관을 나타낸 도이다.
도 2는 MTT 분석법을 통하여 파이퍼 캄보디아눔 추출물이 세포 생존률에 미치는 영향을 확인한 도이다.
도 3은 인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물의 상처 재생 효과를 확인한 도이다.
도 4는 인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물이 유전자 발현에 미치는 영향을 확인한 도이다.
도 5는 인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물이 단백질 발현에 미치는 영향을 확인한 도이다.
도 6은 파이퍼 캄보디아눔 추출물이 UV 조사 후 단백질 발현에 미치는 영향을 확인한 도이다.
도 7은 파이퍼 캄보디아눔 추출물이 UV 조사 후 ROS 활성 변화에 미치는 영향을 확인한 도이다. (ROS-NHDF-control 1: UV를 처리하지 않은 파이퍼 캄보디아눔 처리군, ROS-NHDF-40J/3min: 180초 동안 40J의 UV를 처리한 파이퍼 캄보디아눔 처리군)
도 8은 상처 모델 마우스에서 상처 부위의 비율 변화를 통해 파이퍼 캄보디아눔 추출물의 상처재생 효과를 확인한 도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a view showing the appearance of leaves and trees of Piper Cambodianum used in the present invention. FIG.
FIG. 2 is a graph showing the effect of Piper cambodiae extract on cell viability through MTT assay.
FIG. 3 is a view for confirming wound regeneration effect of Piper cambodia nemium extract in a human dermal fibroblast cell line.
FIG. 4 is a graph showing the effect of Piper cambodiae extract on gene expression in a human dermal fibroblast cell line.
FIG. 5 is a graph showing the effect of Piper cambodiae extract on protein expression in human dermal fibroblast cells.
FIG. 6 is a graph showing the effect of the extract of Piper cambodia on the protein expression after UV irradiation.
FIG. 7 is a graph showing the effect of Piper cambodiae extract on the change of ROS activity after UV irradiation. (ROS-NHDF-control 1: Piper Cambodia treated group without UV treatment, ROS-NHDF-40J / 3 min: Piper Cambodia treated group treated with UV of 40 J for 180 seconds)
8 is a view for confirming the wound regeneration effect of the Piper cambodia nemium extract through a change in the wound area ratio in wound model mice.
본 발명은 파이퍼 캄보디아눔(Piper cambodianum) 추출물을 포함하는 피부개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for improving skin comprising Piper cambodianum extract.
이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 피부개선은 노화방지와 상처개선을 포함한다.Skin improvement in the present invention includes anti-aging and wound healing.
본 발명에서 노화방지는 항산화 효과와 주름개선 효과를 포함한다.In the present invention, anti-aging includes antioxidative effect and wrinkle-reducing effect.
본 발명의 유효성분인 파이퍼 캄보디아눔 추출물은 당업계에 공지된 추출 및 분리 방법을 이용하여 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 '추출물'은 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함한다.The extract of Piper cambodia nem, which is an active ingredient of the present invention, can be obtained by extraction and separation using extraction and separation methods known in the art, and the 'extract' defined in the present invention can be used as crude extract, polar solvent extract Or non-polar solvent-soluble extracts.
상기 파이퍼 캄보디아눔 추출물을 추출하기 위한 추출 용매는 이에 제한되지 않으나, 물, 탄소수 1 내지 4의 알코올 및 이들의 혼합용매로부터 선택된 1종 이상의 용매를 이용할 수 있으며, 바람직하게는 메탄올이다.The extraction solvent for extracting the Piper cambodiaeum extract is not limited thereto, but one or more solvents selected from water, alcohols having 1 to 4 carbon atoms, and a mixed solvent thereof may be used, and methanol is preferably used.
상기 파이퍼 캄보디아눔 추출물은 파이퍼 캄보디아눔의 줄기 또는 잎에서 추출할 수 있다.The Piper Cambodiaeum extract can be extracted from the stem or leaf of Piper Cambodianum.
상기 파이퍼 캄보디아눔 추출물은 파이퍼 캄보디아눔 피 포름(Piper cambodianum P.Fourn) 추출물일 수 있다.The Piper cambodiaeum extract may be a Piper cambodianum P. fourn extract.
상기 파이퍼 캄보디아눔 추출물은 세포외 기질과 관련된 콜라겐, 엘라스틴 또는 HAS-2 유전자의 활성을 증가시키며, MMP-1 유전자의 활성을 억제함으로써 상처치료, 주름개선 및 피부 노화방지 효과를 나타낼 수 있다.The Piper cambodia genus extract may increase the activity of collagen, elastin or HAS-2 gene related to extracellular matrix, and may inhibit the activity of MMP-1 gene, thereby exhibiting wound healing, wrinkle improvement and skin aging prevention effect.
또한 상기 캄보디아눔 추출물은 활성산소종(ROS; reactive oxygen species)의 활성을 억제하며, 이를 통해 산화적 스트레스를 저해하는바, 항산화를 통한 피부 노화방지 효과를 나타낼 수 있다.In addition, the above-mentioned Cambodia genus extract inhibits the activity of reactive oxygen species (ROS), thereby inhibiting oxidative stress and thus exhibiting an anti-aging effect through antioxidation.
또한 상기 파이퍼 캄보디아눔 추출물은 생체 외 및 상처 동물 모델에서 우수한 상처 치료 효과를 나타낼 수 있다.In addition, the above-mentioned Piper cambodiae extract can exhibit an excellent wound healing effect in an in vitro and wound animal model.
따라서, 본 발명에 따른 파이퍼 캄보디아눔 추출물을 피부상태개선을 위한 화장료 조성물에 유효성분으로 포함할 수 있다.Therefore, the extract of Piper cambodiae according to the present invention can be contained as an active ingredient in a cosmetic composition for improving skin condition.
본 발명의 화장료 조성물은 상기 파이퍼 캄보디아눔 추출물과 함께 노화방지 또는 상처 개선 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다.The cosmetic composition of the present invention may contain one or more known active ingredients having antioxidant or wound-improving effect together with the above-mentioned Piper cambodiaeum extract.
본 발명의 화장료 조성물은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 유화 제형의 화장품으로는 영양화장수, 크림, 에센스 등이 있으며, 가용화 제형의 화장품으로는 유연화장수가 있다. 보다 구체적으로, 본 발명의 화장료 조성물은 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 유탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산 제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이, 페이스트, 팩, 세안제, 비누, 계면활성제 함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스, 파운데이션 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 포말 (foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.The cosmetic composition of the present invention can be produced in the form of a general emulsified formulation and a solubilized formulation. Cosmetics of emulsified form include nutrition lotion, cream, essence, etc., and cosmetics of solubilized form have softening longevity. More specifically, the cosmetic composition of the present invention may be in the form of a solution, a gel, a solid or a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, an emulsion, a microemulsion, a microcapsule, The composition of the ionic fibrin dispersant may be in the form of a cream, a skin, a lotion, a powder, an ointment, a spray, a paste, a pack, a cleanser containing a soap, a surfactant, an oil, a powder foundation, an emulsion foundation, a wax, And the like. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant.
본 발명의 화장료 조성물은 유효성분인 파이퍼 캄보디아눔 추출물 이외에 추가로 화장료 조성물에 통상적으로 사용되는 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속 이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부 과학 분야 에서 통상적으로 사용되는 보조제를 추가로 함유할 수 있다. 또한, 상기의 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. The cosmetic composition of the present invention may further contain, in addition to the active ingredient Piper cambodia gum extract, a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents , Lipid vesicles, or any other ingredient commonly used in cosmetics, as well as adjuvants commonly used in the cosmetics or dermatological sciences. In addition, the above ingredients may be introduced in amounts commonly used in the field of dermatology.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 등이 포함될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tracer, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide May be included.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트, 폴리아미드 파우더 등이 포함될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄, 디메틸 에테르 등의 추진체를 포함할 수 있다. When the formulation of the cosmetic composition of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and the like. Carbon, propane / butane, dimethyl ether, and the like.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로 용매, 용해화제, 유탁화제 등이 포함될 수 있고, 구체적으로 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프 로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜, 소르비탄의 지방산 에스테르 등이 포함될 수 있다.When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, the carrier component may include a solvent, a solubilizing agent, and an emulsifying agent. Specific examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Octylene glycol, octylene glycol, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid esters of sorbitan and the like.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로 물, 에탄올, 프로필렌글리콜 등의 액상 희석제; 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르, 폴리옥시에틸렌 소르비탄 에스테르 등의 현탁제; 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가, 트라칸트 등이 포함될 수 있다. When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol, propylene glycol or the like as a carrier component; Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, trachant, and the like.
본 발명의 화장료 조성물의 제형이 계면활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄 올아미드, 식물성유, 라놀린유도체, 에톡실화 글리세롤 지방산 에스테르 등이 포함될 수 있다.When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, ethoxylated glycerol fatty acid ester, and the like.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총 중량에 대하여 바람직하게는 0.01-10% 중량 백분율, 보다 바람직하게는 0.01-5% 중량 백분율로 배합된다.In addition, any of the above components may be compounded within a range that does not impair the objects and effects of the present invention, but is preferably 0.01-10% by weight based on the total weight , More preferably from 0.01% to 5% by weight.
또한 본 발명은 파이퍼 캄보디아눔 추출물을 유효성분으로 포함하는 상처치료용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the treatment of wounds comprising Piper cambodia genome extract as an active ingredient.
본 발명의 약학적 조성물은 상기 파이퍼 캄보디아눔 추출물과 함께 상처 치료 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다.The pharmaceutical composition of the present invention may further contain one or more known active ingredients having wound healing effect together with the above-mentioned Piper cambodiae extract.
본 발명의 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 또한, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌(Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있다. 상기 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로오스, 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral formulations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.
본 발명의 약학적 조성물의 바람직한 투여량은 개체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 바람직한 효과를 위해서, 본 발명의 약학적 조성물은 1일 1 mg/ kg 내지 10000 mg/kg의 양으로 투여할 수 있으며, 하루에 한 번 또는 수 회 나누어 투여할 수 있다.The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the individual, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For a desired effect, the pharmaceutical composition of the present invention may be administered in an amount of 1 mg / kg to 10000 mg / kg per day, and may be administered once or several times a day.
본 발명의 약학적 조성물은 개체에게 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 조성물은 상처 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for wound healing.
또한 본 발명은 파이퍼 캄보디아눔 추출물을 유효성분으로 포함하는 상처치료용 피부외용제 조성물을 제공한다.The present invention also provides a composition for external application for skin for wound healing, which comprises Piper cambodia genome extract as an active ingredient.
본 발명의 피부외용제 조성물은 상기 파이퍼 캄보디아눔 추출물과 함께 상처 치료 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다.The composition for external application for skin of the present invention may further contain one or more known active ingredients having wound healing effect together with the above-mentioned Piper cambodia nymph extract.
본 발명의 피부외용제 조성물은 신체 부위에 따라 그 제형이 특별히 한정되지 않으며, 당업계의 공지기술을 참조하여 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 액제, 연고제, 크림제, 로션제, 스프레이제, 패취제, 오일제, 왁스제, 유탁액제, 현탁액제, 겔제 또는 에어로졸제 등 형태로 사용될 수 있으나, 이에 한정되는 것은 아니다. The composition for external application for skin of the present invention is not particularly limited depending on the body part, and may be prepared in any formulations conventionally prepared by referring to known techniques in the art. For example, it can be used in the form of liquid, ointment, cream, lotion, spray, patch, oil, wax, emulsion, suspension, gel or aerosol.
본 발명의 피부외용제 조성물은 통상적인 첨가제, 예를 들어 보존제, 의약 침투를 보조하는 용매, 연고 및 크림의 경우 연화제 등을 포함할 수 있으며, 에탄올 또는 올레일 알코올과 같은 통상적 담체를 함유할 수 있다.The composition for external application for skin of the present invention may contain conventional additives such as preservatives, solvents to assist drug penetration, softening agents for ointments and creams, and the like, and may contain conventional carriers such as ethanol or oleyl alcohol .
본 발명의 피부외용제 조성물은 상술한 성분에 한정되지 않고, 필요에 따라 통상의 화장료 조성물 또는 약학 조성물에 배합되는 다른 성분을 포함할 수 있다. 예를 들어, 유지 성분, 보습제, 에몰리엔트제, 계면활성제, 유기 또는 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 포함할 수 있다.The composition for external application for skin of the present invention is not limited to the above-mentioned components, and may include other components to be incorporated into a usual cosmetic composition or pharmaceutical composition, if necessary. For example, it is possible to use a water-soluble organic solvent such as a preservative, a humectant, an emollient, a surfactant, an organic or inorganic pigment, an organic powder, an ultraviolet absorbent, an antiseptic, a bactericide, an antioxidant, a plant extract, Cold agents, antiperspirants, purified water, and the like.
또한 본 발명은 파이퍼 캄보디아눔 추출물을 유효성분으로 포함하는 항산화 또는 상처개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for antioxidant or wound healing, which comprises Piper cambodia genus extract as an active ingredient.
본 발명의 건강기능식품은 상기 파이퍼 캄보디아눔 추출물과 함께 항산화 또는 상처 개선 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다.The health functional food of the present invention may contain at least one known active ingredient having an antioxidant or wound-improving effect together with the above-mentioned Piper cambodiaeum extract.
본 발명에서, "건강기능식품"이란, 질병의 예방 및 개선, 생체방어, 면역, 병후의 회복, 노화 억제 등 생체조절 기능을 가지는 식품을 말하는 것으로, 장기적으로 복용하였을 때 인체에 무해해야 한다.In the present invention, the term "health functional food" refers to a food having a biological control function such as prevention and improvement of disease, bio-defense, immunity, recovery after disease and aging inhibition.
본 발명의 파이퍼 캄보디아눔 추출물을 식품 첨가물로 사용할 경우, 상기 파이퍼 캄보디아눔 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 파이퍼 캄보디아눔 추출물은 원료에 대하여 15중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the Piper cambodiae extract of the present invention is used as a food additive, the Piper Cambodiaeum extract may be directly added or used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the Piper cambodiae extract of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토오스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml 당 일반적으로 약 0.01 내지 10 g, 바람직하게는 약 0.01 내지 0.1 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명은 이해를 돕기 위하여 바람직한 실시예, 실험예 및 제조예를 제시한다. 다만 하기의 실시예, 실험예 및 제조예는 본 발명의 내용을 예시하는 것일 뿐 본 발명를 한정하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to preferred embodiments, experimental examples, and production examples. However, the following Examples, Experimental Examples and Preparation Examples are intended only to illustrate the contents of the present invention and not to limit the present invention.
실시예 1. 파이퍼 캄보디아눔 추출물의 제조Example 1 Preparation of Piper Cambodiae Extract
베트남이 원산지인 파이퍼 캄보디아눔 피 포름(Piper cambodianum P.Fourn) 의 줄기와 잎을 메탄올로 추출한 것을 생명공학연구원 해외허브센터에서 공급받아 사용하였다 (분양번호 FBM151-010, 바코드 PBVN12811). 사용한 파이퍼 캄보디아눔의 줄기와 잎의 모양을 도 1에 나타내었다.The stem and leaves of Piper cambodianum P. Fourn originating in Vietnam were extracted from methanol by the International Center for Biotechnology (FBN151-010, Barcode PBVN12811). The stem and leaves of the used Piper Cambodianum are shown in Fig.
실시예 2. 인간 피부 섬유아(NHDF; Normal Human Dermal Fibroblast) 세포주 배양 방법Example 2 Culture of Human Human Dermal Fibroblast (NHDF) Cell Lines
인간 피부 섬유아 세포주의 배양을 위해 둘베코의 변형된 이글스 배지(DMEM; Dulbecco's modified Eagle's medium)에 우태아 혈청 10 %, 항생제 1 %를 첨가한 후 37 ℃의 5 % CO2 배양기에서 배양하여 사용하였다.For the cultivation of human dermal fibroblast cells, 10% fetal bovine serum and 1% antibiotics were added to Dulbecco's modified Eagle's medium (DMEM) and cultured in a 5% CO 2 incubator at 37 ° C Respectively.
실험예 1. MTT 분석법(Assay)를 통한 파이퍼 캄보디아눔 추출물이 세포 성장률에 미치는 영향 확인Experimental Example 1. Determination of the effect of Piper Cambodiaeum extract on cell growth rate by MTT assay (Assay)
파이퍼 캄보디아눔 추출물의 세포 생존률을 확인을 위하여 MTT 분석법을 수행하였다. 먼저, 인간 피부 섬유아 세포주(NHDF)를 96웰 플레이트에 1X103 개씩 분주하고 24시간 동안 상기 실시예 2와 동일한 방법으로 배양하였으며, 다음날 상기 실시예 1에서 얻은 파이퍼 캄보디아눔 추출물을 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml의 농도로 웰 당 100 μl씩 첨가한 후 24시간 동안 배양하였다. 대조군에는 파이퍼 캄보디아눔 추출물을 미처리하였다. 24시간 후 각 웰 당 90 μl의 새 배지에 Ez-Cyto(MTT) 시약 10 μl을 넣은 후 30분 동안 유지하다 배양한 색이 변하기 시작하면 450 nm(기준 650 nm)의 파장에서의 흡광도를 측정하였으며, 그 결과를 도 2에 나타내었다.MTT assay was performed to confirm the cell viability of Piper cambodiae extract. First, human dermal fibroblast cell line (NHDF) was dispensed into 96-well plates in an amount of 1 × 10 3 , and cultured for 24 hours in the same manner as in Example 2. The following day, the extract of Piper cambodiaum obtained in Example 1 was added at 1 μg / ml, 10 μg / ml and 50 μg / ml, and the cells were cultured for 24 hours. In the control group, Piper Cambodiaeum extract was not treated. After 24 hours, add 10 μl of Ez-Cyto (MTT) reagent to 90 μl of fresh medium per well and incubate for 30 minutes. When the color change begins, measure the absorbance at 450 nm (650 nm) The results are shown in FIG.
도 2에 나타낸 바와 같이, 파이퍼 캄보디아눔 추출물의 농도가 증가하여도 세포 생존률에는 크게 변화가 없어, 상기 추출물은 세포 독성이 없음을 확인하였다.As shown in FIG. 2, even when the concentration of Piper cambodiae extract was increased, there was no significant change in cell viability, and it was confirmed that the extract had no cytotoxicity.
실험예 2. 인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물의 상처재생효과 확인Experimental Example 2. Confirmation of wound regeneration effect of Piper cambodiaeum extract on human dermal fibroblast cell line
파이퍼 캄보디아눔 추출물의 상처재생효과를 확인하기 위하여 인간 피부 섬유아 세포주를 이용하였다. 상기 실시예 2와 동일한 조건에서 배양한 인간 피부 섬유아 세포주를 6 웰 플레이트 중 4 웰에 각각 106개씩 분주하고, 다음 날 세포가 약 70 % 이상 자랐을 때 10 μl용 피펫을 이용하여 동일한 간격으로 세포 표면을 긁었다. 대조군인 웰에는 아무것도 첨가하지 않고 새 배지를 2 ml 넣어주었으며, 실험군인 나머지 세 개의 웰에는 배지 2 ml에 파이퍼 캄보디아눔 추출물을 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml의 농도로 첨가하였다. 24시간 동안 배양 후 현미경으로 그 이미지를 확인하였다. 그 결과를 도 3에 나타내었다.Human dermal fibroblast cell line was used to confirm wound regeneration effect of Piper cambodiaeum extract. The human dermal fibroblast cells cultured under the same conditions as in Example 2 were divided into 4 wells of each of the 6 well plates at a rate of 10 6 , and when the cells were grown by about 70% the next day, Scratched cell surface. 2 ml of the fresh medium was added to the well, which was not added to the control well. In the remaining three wells of the experimental group, 2 ml of the culture medium contained 1 μg / ml, 10 μg / ml and 50 μg / ml of Piper cambodia . After incubation for 24 hours, the images were confirmed under a microscope. The results are shown in Fig.
도 3에 나타낸 바와 같이, 파이퍼 캄보디아눔 추출물의 농도가 증가함에 따라 인간 피부 섬유아 세포주에서 상처재생이 잘 되는 것을 확인할 수 있었다. 이는 파이퍼 캄보디아눔 추출물이 농도의존적 상처재생효과를 가짐을 나타낸다.As shown in FIG. 3, it was confirmed that the wound regeneration was well performed in the human dermal fibroblast cell line as the concentration of the Piper cambodia genome extract increased. This indicates that the Piper cambodiae extract has a concentration dependent wound regeneration effect.
실험예 3. Q-PCR을 통한 인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물이 유전자 발현에 미치는 영향 확인Experimental Example 3. Confirmation of effect of Piper Cambodiae Extract on gene expression in human dermal fibroblast line through Q-PCR
인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔이 유전자 발현 수준에 미치는 영향을 확인하기 위해 상기 실시예 2와 동일한 방법으로 배양한 인간 피부 섬유아 세포주를 6 웰 플레이트에 각각 3X105개씩 분주하고, 새 배지에 파이퍼 캄보디아눔 추출물을 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml의 농도로 처리한 후 24 시간 동안 배양하였다. 대조군에는 파이퍼 캄보디아눔 추출물을 미처리하였다. 이 후 각 웰을 1X PBS로 세척한 후 상용화된 RNA 추출 키트(Nanohelix; Pure Helix RNA Extraction Solution Nanohelix)를 이용하여 제공된 프로토콜에 따라 mRNA를 추출한 뒤 GE Nano vue로 정량하였다. Q-PCR 실시를 위해 cDNA합성 키트를 이용하여 mRNA로부터 cDNA를 합성하고, 세포외 기질 활성 유전자인 콜라겐, 엘라스틴, HAS-2 및 세포간 기질 분해 효소인 MMP-1의 활성을 확인하였다.In order to confirm the effect of Piper cambodia on the gene expression level in human dermal fibroblast cell line, 3 x 10 5 human fibroblast cell lines cultured in the same manner as in Example 2 were dispensed into 6-well plates, Piper cambodiae extracts were treated at a concentration of 1 μg / ml, 10 μg / ml and 50 μg / ml, respectively, and cultured for 24 hours. In the control group, Piper Cambodiaeum extract was not treated. After washing each well with 1X PBS, mRNA was extracted according to the protocol provided by using a commercially available RNA extraction kit (Nanohelix; Pure Helix RNA Extraction Solution Nanohelix) and quantitated with GE Nano vue. For Q-PCR, cDNA was synthesized from mRNA using a cDNA synthesis kit and the activity of extracellular matrix active genes, collagen, elastin, HAS-2 and intercellular protease, MMP-1, was confirmed.
이때, 이용한 프라이머는 하기 표 1에 나타내었으며, PCR Cycle은 하기 표 2에 나타내었다. 결과의 통계처리는 평균 반복 역치값(normalized cycle threshold; CT)과 표준편차 값을 구하고, 편도 ANOVA(one-way ANOVA)로 분석한 후에 p<0.05 수준에서 유의성을 검증하였으며, 항존유전자로 GAPDH의 활성을 비교하여 보정하였다. 그 결과를 도 4에 나타내었다.The primers used are shown in Table 1 below, and the PCR cycles are shown in Table 2 below. The statistical analysis of the results was performed using the one-way ANOVA (ANOVA) and the normalized cycle threshold (CT), and the significance was tested at the p <0.05 level. The GAPDH Activity was compared and corrected. The results are shown in Fig.
도 4에서 나타낸 바와 같이, 파이퍼 캄보디아눔 추출물의 농도가 증가함에 따라 콜라겐, 엘라스틴, HAS-2의 발현이 증가하고, MMP-1의 발현은 감소하는 것을 확인하였다. 이는 파이퍼 캄보디아눔 추출물이 MMP-1의 발현을 억제하고 및 이에 따른 콜라겐, 엘라스틴, HAS-2(hyaluronan synthase 2)의 발현을 증가시켜 세포 탄성 재건 능력 향상을 통한 상처치료 및 주름개선 등 노화방지 효과를 가짐을 나타낸다.As shown in FIG. 4, it was confirmed that the expression of collagen, elastin, and HAS-2 was increased and the expression of MMP-1 was decreased as the concentration of Piper cambodia genome extract increased. This is because the extract of Piper cambodia suppresses the expression of MMP-1 and thereby increases the expression of collagen, elastin, and hyaluronan synthase 2 (HAS-2) .
실험예 4. 인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물이 단백질 활성에 미치는 영향 확인EXPERIMENTAL EXAMPLE 4 Confirmation of Effect of Piper Cambodiae Extract on Protein Activity in Human Dermal Fibroblast Cell Lines
인간 피부 섬유아 세포주에서 파이퍼 캄보디아눔 추출물이 단백질 활성에 미치는 효과를 확인하기 위하여, 상기 실시예 2와 같이 배양한 인간 피부 섬유아 세포주를 6 웰 플레이트에 각각 1X106개씩 분주하였다. 대조군에는 아무것도 첨가하지 않은 새 배지를 2 ml씩만 넣어주고, 나머지 세 개의 실험군에는 배지 2 ml에 파이퍼 캄보디아눔 추출물을 농도별로 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml의 농도로 처리하고, 24시간 동안 배양하였다. 그 후 배지를 제거하고, 1X PBS로 세척하였으며 세포 용해 버퍼(lysis buffer)로 단백질을 추출하고 정량화하였다. 이 후 웨스턴 블로팅(western blot)을 수행하여 세포 외 기질 활성 단백질인 콜라겐, 엘라스틴 및 ERK2와 활성 억제 단백질인 MMP-3의 활성을 확인하였으며, 그 결과를 도 5에 나타내었다.In order to confirm the effect of Piper cambodiae extract on the activity of the protein in the human dermal fibroblast cell line, the human dermal fibroblast cell line cultured as in Example 2 was dispensed into 6-well plates at 1 × 10 6 cells. 2 ml of fresh medium containing no additions was added to the control, and in the remaining three experimental groups, 2 ml of the medium was treated with 1 μg / ml, 10 μg / ml and 50 μg / ml of the extract of Piper cambodiae And cultured for 24 hours. After that, the medium was removed, washed with 1X PBS, and proteins were extracted and quantified with a lysis buffer. Western blotting was performed to confirm the activity of collagen, elastin and ERK2, which are extracellular matrix active proteins, and MMP-3, an activity-inhibiting protein, and the results are shown in FIG.
도 5에 나타낸 바와 같이, 파이퍼 캄보디아눔 추출물의 농도가 증가함에 따라 인간 피부 섬유아 세포주에서 콜라겐, 엘라스틴 및 ERK2 단백질의 발현양은 증가하고, MMP-3의 발현양은 감소하는 결과를 확인하였다. 이는 파이퍼 캄보디아눔 추출물이 콜라겐, 엘라스틴 및 ERK2 합성 증가를 통해 세포 탄성 재건 능력을 향상시켜 주름을 개선하며 상처치료 효과를 가짐을 나타낸다.As shown in FIG. 5, the expression levels of collagen, elastin and ERK2 protein in the human dermal fibroblast cell line were increased and the expression level of MMP-3 was decreased as the concentration of Piper cambodiae extract increased. This indicates that the extract of Piper cambodiae improves the ability of cell elastic reconstruction by increasing the synthesis of collagen, elastin and ERK2, thereby improving wrinkles and having wound healing effect.
실험예 5. 파이퍼 캄보디아눔 추출물이 UV 조사 후 단백질 활성에 미치는 영향 확인Experimental Example 5. Confirmation of Effect of Piper Cambodiae Extract on Protein Activity after UV Irradiation
노화를 유발하는 것으로 알려진 UV 조사 후 파이퍼 캄보디아눔 추출물이 단백질 활성에 미치는 영향을 확인하기 위하여, 상기 실시예 2와 같이 배양한 인간 피부 섬유아 세포주를 6 웰 플레이트에 각각 1X106개씩 분주하고 30 초 동안 40 J의 UV를 조사하였다. 대조군에는 새 배지를 2 ml씩만 넣어주고, 나머지 세 개의 실험군에는 배지 2 ml에 파이퍼 캄보디아눔 추출물을 농도별로 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml씩 넣어주고, 24 시간 동안 배양하였다. 그 후 배지를 제거하고 1X PBS로 세척하였으며 세포 용해 버퍼(lysis buffer)로 단백질을 추출 및 정량하였다. 이 후 웨스턴 블로팅(western blot)을 통해 UV에 의해 활성화되는 것으로 알려진 TNFR, EGFR과 p38, p53 및 cJUN의 활성을 확인하였으며, 그 결과를 도 6에 나타내었다.In order to confirm the effect of the Piper cambodiaeum extract on the protein activity after UV irradiation, which is known to cause aging, the human dermal fibroblast cultured as described in Example 2 was dispensed into 6 well plates at a rate of 1 × 10 6 , Gt; UV < / RTI > 2 ml of fresh medium was added to the control group, and 1 μg / ml, 10 μg / ml and 50 μg / ml of Piper cambodia nymph extract were added to 2 ml of the medium in the remaining three experimental groups and cultured for 24 hours Respectively. Then, the medium was removed, washed with 1X PBS, and proteins were extracted and quantified with a lysis buffer. Thereafter, the activity of TNFR, EGFR, p38, p53 and cJUN, which are known to be activated by UV through western blotting, was confirmed, and the results are shown in Fig.
도 6에 나타낸 바와 같이, 파이퍼 캄보디아눔 추출물을 처리한 실험군에서 농도의존적으로 UV에 활성화되는 것으로 알려진 TNFR, EGFR, p38, p53과 cJUN 활성이 감소됨을 확인하였다. 이는 파이퍼 캄보디아눔이 UV 조사에 의해 조절되는 하위 단백질들의 활성을 억제함으로써 항산화 및 이에 따른 항노화 효과가 있음을 나타낸다.As shown in FIG. 6, it was confirmed that TNFR, EGFR, p38, p53 and cJUN activity, which are known to be activated by UV in a dose dependent manner, are reduced in the experimental group treated with Piper cambodiaeum extract. This indicates that Piper cambodium has antioxidative and thus anti-aging effects by inhibiting the activity of the sub-proteins regulated by UV irradiation.
실험예 6. 파이퍼 캄보디아눔 추출물이 UV 조사 후 ROS 활성 변화에 미치는 영향 확인Experimental Example 6. Determination of Effect of Piper Cambodiae Extract on Changes in ROS Activity after UV Irradiation
UV 조사 후 파이퍼 캄보디아눔 추출물이 ROS 활성에 미치는 효과를 확인하기 위하여, 상기 실시예 2와 같이 배양한 인간 피부 섬유아 세포주를 6 웰 플레이트에 각각 1X106개씩 분주하고 30 초 동안 40 J로 UV를 조사하였으며 실험군인 세 개의 웰에는 배지 2 ml에 파이퍼 캄보디아눔 추출물을 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml의 농도로 첨가한 후 24 시간 동안 배양 하였다. 대조군에는 파이퍼 캄보디아눔 추출물을 미처리하였다. 그 후 DCFDA(2',7'-dichlorofluorescin diacetate)와 CM-H2DCFDA를 넣고 30 분 동안 전처리한 후 FACS(Flow Cytometery)로 ROS 생성을 측정하였으며, 그 결과를 도 7에 나타내었다.In order to confirm the effect of the Piper cambodiaeum extract on the activity of ROS after UV irradiation, the human skin fibroblast cells cultured in the same manner as in Example 2 were dispensed into 6-well plates at a rate of 1 × 10 6 cells / To the three wells of the experimental group, 2 ml of the culture medium was added at a concentration of 1 μg / ml, 10 μg / ml and 50 μg / ml, respectively, and cultured for 24 hours. In the control group, Piper Cambodiaeum extract was not treated. Then, DCFDA (2 ', 7'-dichlorofluorescin diacetate) and CM-H2DCFDA were added and pretreated for 30 minutes, and ROS production was measured by FACS (Flow Cytometry). The results are shown in FIG.
도 7에 나타낸 바와 같이, UV를 조사한 경우 ROS 생성이 증가하였으나, 파이퍼 캄보디아눔 추출물을 처리한 경우 이러한 ROS 생성이 확연히 감소함을 확인하였다. 이는 파이퍼 캄보디아눔이 ROS 생성을 억제함으로서 항산화 및 이에 따른 항노화 효과가 있음을 나타낸다.As shown in FIG. 7, it was confirmed that ROS production was increased when irradiated with UV, but that ROS production was significantly decreased when Piper Cambodia rum extract was treated. This indicates that Piper cambodia num inhibits ROS production and thus has antioxidative and anti-aging effects.
실험예 7. 파이퍼 캄보디아눔 추출물의 Experimental Example 7: Preparation of Piper Cambodiae Extract in vivoin vivo 에서 상처재생효과 확인 Check the effect of wound regeneration in
파이퍼 캄보디아눔 추출물의 상처재생 효과를 확인하기 위하여 상처 모델 마우스의 등을 제모하여 동일한 크기로 상처 4 곳을 낸 후, 대조군인 한 상처부위는 파이퍼 캄보디아눔 추출물을 처리하지 않고, 실험군인 나머지 세 상처부위에는 파이퍼 캄보디아눔 추출물을 각각 1 μg/ml, 10 μg/ml 및 50 μg/ml의 농도로 처리한 후 하루 단위로 사진을 찍어 관찰하였으며, 그 결과를 도 8에 나타내었다.In order to confirm the wound regeneration effect of Piper cambodiae extract, the injured model mouse's epilator was removed and four scars were wound in the same size. One wound area as a control was not treated with the Piper Cambodianum extract, , And Piper cambodiae extract was treated at a concentration of 1 μg / ml, 10 μg / ml and 50 μg / ml, respectively, and then photographed every day. The results are shown in FIG.
도 8에 나타낸 바와 같이, 파이퍼 캄보디아눔 추출물을 처리한 실험군에서 상처 크기가 작아짐을 확인하였고, 이러한 효과는 농도가 증가함에 따라 그 효과가 더 현저하게 나타남을 확인하였다. 이는 파이퍼 캄보디아눔 추출물이 in vivo에서 상처치료 효과가 있음을 나타낸다.As shown in FIG. 8, it was confirmed that the wound size decreased in the experimental group treated with the Piper cambodia genome extract, and the effect was more remarkable as the concentration increased. This indicates that Piper cambodiaeum extract has an effect of wound healing in vivo .
상기 실험들의 통계는 ±S.D를 사용하였고, p<0.05(*), p<0.01로 기록하였다.The statistics of the experiments were ± SD and were recorded as p <0.05 (*), p <0.01.
이상의 실험 결과를 통하여, 본 발명에 따른 파이퍼 캄보디아눔 (Piper cambodianum) 추출물은 콜라겐(collagen), 엘라스틴(Elastin) 및 HAS-2 유전자의 발현을 증가시키고 MMP-1 유전자의 발현 및 ROS 활성을 저해함으로써 우수한 상처치료 및 항노화 효과를 나타낼 수 있는바 화장료 조성물, 약학적 조성물, 피부외용제 조성물 및 건강기능식품 조성물 등으로 다양하게 활용할 수 있음을 확인하였다.The Piper cambodianum extract according to the present invention increased the expression of collagen, elastin and HAS-2 gene and inhibited the expression of MMP-1 gene and ROS activity Which can exhibit excellent wound healing and anti-aging effects, and that it can be used variously as a cosmetic composition, a pharmaceutical composition, a composition for external application for skin, and a health functional food composition.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
제제예 1. 화장료 제제의 제조Formulation Example 1. Preparation of cosmetic preparation
1. 유연화장수 제조1. Flexible longevity manufacturing
파이퍼 캄보디아눔 추출물 0.1중량%0.1% by weight of Piper cambodiae extract
1,3-부틸렌글리콜 5.2중량%, 올레일알코올 1.5중량%5.2% by weight of 1,3-butylene glycol, 1.5% by weight of oleyl alcohol,
에탄올 3.2중량%3.2% by weight of ethanol
폴리솔베이트 20 3.2중량%Polysorbate 20 3.2 wt%
벤조페논-9 2.0중량%Benzophenone-9 2.0 wt%
카르복실비닐폴리머 1.0중량%, 글리세린 3.5중량%1.0% by weight of a carboxyl vinyl polymer, 3.5% by weight of glycerin,
미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 유연화장수를 제조하였다.A minor amount of fragrance, a small amount of preservative, and a remaining amount of purified water were mixed to prepare a softening water by a conventional method.
2. 밀크로션 제조2. Milk lotion manufacturing
파이퍼 캄보디아눔 추출물 0.1중량%0.1% by weight of Piper cambodiae extract
글리세린 5.1중량%Glycerin 5.1 wt%
프로필렌글리콜 4.2중량%Propylene glycol 4.2 wt%
토코페릴아세테이트 3.0중량%3.0% by weight of tocopheryl acetate
유동파라핀 4.6중량%Liquid paraffin 4.6 wt%
트리에탄올아민 1.0중량%1.0% by weight triethanolamine
스쿠알란 3.1중량%Squalane 3.1 wt%
마카다미아너트오일 2.5중량%Macadamia nut oil 2.5 wt%
폴리솔베이트 60 1.6중량%Polysorbate 60 1.6 wt%
비탄세스퀴롤레이트 1.6중량%1.6% by weight < RTI ID = 0.0 >
프로필파라벤 0.6중량%Propyl paraben 0.6 wt%
카르복실비닐폴리머 1.5중량%Carboxyl vinyl polymer 1.5 wt%
미량의 향, 미량의 방부제, 잔량의 정제수를 혼합하여 통상의 방법으로 밀크로션을 제조하였다.A minor amount of fragrance, a small amount of preservative, and a remaining amount of purified water were mixed to prepare an milk lotion by a conventional method.
3. 영양크림 제조3. Nutritional cream manufacturing
파이퍼 캄보디아눔 추출물 0.5중량%0.5% by weight of Piper cambodiae extract
글리세린 4.0중량%Glycerin 4.0 wt%
바셀린 3.5중량%Vaseline 3.5 wt%
트리에탄올아민 2.1중량%2.1% by weight triethanolamine
유동파라핀 5.3중량%Liquid paraffin 5.3 wt%
스쿠알란 3.0중량%Squalane 3.0 wt%
밀납 2.6중량%Wax 2.6 wt%
토코페릴아세테이트 5.4중량%Tocopheryl acetate 5.4 wt%
폴리솔베이트 60 3.2중량%Polysorbate 60 3.2 wt%
카르복실비닐폴리머 1.0중량%Carboxyl vinyl polymer 1.0 wt%
솔비탄세스퀴올레이트 3.1중량%3.1 weight percent sorbitan sesquioleate
미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 영양크림을 제조하였다.A minor amount of fragrance, a small amount of preservative, and a remaining amount of purified water were mixed to prepare a nutritional cream by a conventional method.
4. 마사지크림 제조4. Massage cream manufacturing
파이퍼 캄보디아눔 추출물 0.5중량%0.5% by weight of Piper cambodiae extract
글리세린 4.0중량%Glycerin 4.0 wt%
바셀린 3.5중량%, 트리에탄올아민 0.5중량%3.5% by weight of petrolatum, 0.5% by weight of triethanolamine,
유동파라핀 24.0중량%Liquid paraffin 24.0 wt%
스쿠알란 3.0중량%, 밀납 2.1중량%Squalane 3.0 wt%, wax 2.1 wt%
토코페릴아세테이트 0.1중량%0.1% by weight of tocopheryl acetate
폴리솔베이트 60 2.4중량%Polysorbate 60 2.4 wt%
카르복실비닐폴리머 1.0중량%Carboxyl vinyl polymer 1.0 wt%
솔비탄세스퀴올레이트 2.3중량%2.3 weight% sorbitan sesquioleate
미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 마사지크림을 제조하였다.A minor amount of fragrance, a small amount of preservative and a remaining amount of purified water were mixed to prepare a massage cream by a conventional method.
제제예 2. 약학적 제제의 제조Formulation Example 2. Preparation of pharmaceutical preparations
1. 산제의 제조 1. Manufacturing of powder
파이퍼 캄보디아눔 추출물 20 mgPiper cambodiae extract 20 mg
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above components are mixed and filled in airtight bags to prepare powders.
2. 정제의 제조2. Preparation of tablets
파이퍼 캄보디아눔 추출물 10 mgPiper cambodiae extract 10 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
3. 캡슐제의 제조3. Preparation of capsules
파이퍼 캄보디아눔 추출물 10 mgPiper cambodiae extract 10 mg
결정성 셀룰로오스 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
4. 주사제의 제조4. Preparation of injections
파이퍼 캄보디아눔 추출물 10 mgPiper cambodiae extract 10 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO42H2O 26 mgNa 2 HPO 4 2H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ml) 상기의 성분 함량으로 제조한다.(2 ml) per 1 ampoule in accordance with the usual injection preparation method.
5. 액제의 제조5. Manufacture of liquids
파이퍼 캄보디아눔 추출물 20 mg Piper cambodiae extract 20 mg
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
제제예 3. 식품 제제의 제조Formulation Example 3. Preparation of food preparation
1. 건강식품의 제조1. Manufacture of health food
파이퍼 캄보디아눔 추출물 100 mg
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 g 70 g of vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 g 0.2 g of vitamin B12
비타민 C 10 mg
비오틴 10 g Biotin 10 g
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 g Folate 50 g
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
2. 건강음료의 제조2. Manufacture of health drinks
파이퍼 캄보디아눔 추출물 100 mg
비타민 C 15 gVitamin C 15 g
비타민 E(분말) 100 gVitamin E (powder) 100 g
젖산철 19.75 g19.75 g of ferrous lactate
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinic acid amide 3.5 g
비타민 A 0.2 gVitamin A 0.2 g
비타민 B1 0.25 gVitamin B1 0.25 g
비타민 B2 0.3 gVitamin B2 0.3 g
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered, sterilized in a sterilized 2 L container, sealed, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
Claims (11)
A cosmetic composition for improving skin comprising Piper cambodianum extract.
2. The method of claim 1, wherein the Piper cambodiae extract is selected from the group consisting of Piper cambodianum P. Fourn). ≪ / RTI >
The cosmetic composition for skin improvement according to claim 1, wherein the skin improving agent is for improving wrinkles or preventing aging.
The cosmetic composition for improving skin according to claim 1, wherein the skin improving agent is for wound healing.
The cosmetic composition for skin improvement according to claim 1, wherein the extract is extracted with water, a C 1 -C 4 alcohol, or a mixed solvent thereof.
The cosmetic composition for skin improvement according to claim 1, wherein the extract is extracted from a stem or a leaf.
The cosmetic composition for skin improvement according to claim 1, wherein the extract increases the expression of at least one gene selected from the group consisting of collagen, elastin, and hyaluronan synthase 2 (HAS-2) genes .
The cosmetic composition for skin improvement according to claim 1, wherein the extract inhibits the activity of ROS (reactive oxygen species).
A pharmaceutical composition for the treatment of wounds comprising Piper cambodianum extract.
A composition for external application for skin for wound healing comprising Piper cambodianum extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160047400A KR101853711B1 (en) | 2016-04-19 | 2016-04-19 | Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160047400A KR101853711B1 (en) | 2016-04-19 | 2016-04-19 | Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170119422A true KR20170119422A (en) | 2017-10-27 |
KR101853711B1 KR101853711B1 (en) | 2018-05-02 |
Family
ID=60300297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160047400A KR101853711B1 (en) | 2016-04-19 | 2016-04-19 | Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101853711B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190113242A (en) | 2018-03-28 | 2019-10-08 | 주식회사 메가코스바이오 | composition having anti-aging activity by using tomato and chestnut shell extract |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102478583B1 (en) * | 2018-05-18 | 2022-12-16 | 한국한의학연구원 | Composition for wound healing or skin regeneration comprising Aster koraiensis extract or fraction thereof |
-
2016
- 2016-04-19 KR KR1020160047400A patent/KR101853711B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190113242A (en) | 2018-03-28 | 2019-10-08 | 주식회사 메가코스바이오 | composition having anti-aging activity by using tomato and chestnut shell extract |
Also Published As
Publication number | Publication date |
---|---|
KR101853711B1 (en) | 2018-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101931978B1 (en) | Composition for enhancing whitening | |
KR20150057917A (en) | Composition for skin whitening | |
KR101743200B1 (en) | Composition for skin whitening comprising fraction of fruit extract of Sageretia thea as effective component | |
KR20180077927A (en) | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof | |
JP5773111B2 (en) | Composition for inhibiting skin pigmentation and use thereof | |
CN101472597B (en) | Inhibitor of expression of nuclear transcription factor AP-1, and pharmaceutical product and product using the inhibitor | |
KR101853711B1 (en) | Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum | |
KR20170025367A (en) | Composition for improving skin | |
CN113613666A (en) | Composition for relieving skin irritation and protecting skin caused by environmental pollution factor comprising myristica fragrans extract or macelignan as effective ingredient | |
KR101907919B1 (en) | Composition for preventing or improving skin wrinkle comprising Siraitia grosvenori residual extract as effective component | |
KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
KR101863895B1 (en) | Composition for skin whitening comprising Stachys sieboldii extract fermented using Hericium erinaceum mycelium as effective component | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR20150087141A (en) | Composition for improving skin | |
KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
KR20190063171A (en) | Composition comprising extract of solanum nigrum or solsonine as an effective ingredient for preventing skin aging or improving skin wrinkle | |
KR102577528B1 (en) | Composition for improving skin | |
KR102224313B1 (en) | Composition for skin whitening comprising scutellaria alpina extract | |
KR101574765B1 (en) | Cosmetic or pharmaceutical composition for skin whitening comprising saikosaponin D | |
KR101577787B1 (en) | Composition for skin whitening comprising polyphyllin vii | |
KR20180120120A (en) | Composition for skin anti-aging or moisturization comprising extract of marian plum | |
KR20150019678A (en) | Composition for skin whitening | |
JP2011032176A (en) | Melanin production promoter | |
KR20170025365A (en) | Composition for improving skin | |
KR20170099669A (en) | Composition for improving skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |